Dianthus Therapeutics logo

Dianthus TherapeuticsNASDAQ: DNTH

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 June 2018

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$813.41 M
-14%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector
-59%vs. 3y high
61%vs. sector
197.52
-41%vs. 3y high
96%vs. sector

Price

after hours | Fri, 25 Oct 2024 20:02:32 GMT
$27.71-$0.23(-0.82%)

Dividend

No data over the past 3 years
$1.86 M$650.00 K
$1.86 M-$17.61 M

Analysts recommendations

Institutional Ownership

DNTH Latest News

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
globenewswire.com15 October 2024 Sentiment: POSITIVE

NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia.

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
zacks.com09 October 2024 Sentiment: POSITIVE

Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
globenewswire.com08 August 2024 Sentiment: POSITIVE

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing;  top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June;  top-line results anticipated in 2H'26 Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to initiate 2H'24  Approximately $361 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2024, and provided an update on recent business achievements.

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
zacks.com08 July 2024 Sentiment: POSITIVE

Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
globenewswire.com28 June 2024 Sentiment: POSITIVE

NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.

What type of business is Dianthus Therapeutics?

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

What sector is Dianthus Therapeutics in?

Dianthus Therapeutics is in the Healthcare sector

What industry is Dianthus Therapeutics in?

Dianthus Therapeutics is in the Biotechnology industry

What country is Dianthus Therapeutics from?

Dianthus Therapeutics is headquartered in United States

When did Dianthus Therapeutics go public?

Dianthus Therapeutics initial public offering (IPO) was on 21 June 2018

What is Dianthus Therapeutics website?

https://dianthustx.com

Is Dianthus Therapeutics in the S&P 500?

No, Dianthus Therapeutics is not included in the S&P 500 index

Is Dianthus Therapeutics in the NASDAQ 100?

No, Dianthus Therapeutics is not included in the NASDAQ 100 index

Is Dianthus Therapeutics in the Dow Jones?

No, Dianthus Therapeutics is not included in the Dow Jones index

When was Dianthus Therapeutics the previous earnings report?

No data

When does Dianthus Therapeutics earnings report?

The next expected earnings date for Dianthus Therapeutics is 08 November 2024